Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (20)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Barchiesi, F.
Right arrow Articles by Scalise, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Barchiesi, F.
Right arrow Articles by Scalise, G.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of Antimicrobial Chemotherapy (2001) 48, 769-773
© 2001 The British Society for Antimicrobial Chemotherapy

Activity of the new antifungal triazole, posaconazole, against Cryptococcus neoformans

Francesco Barchiesia,*, Anna Maria Schimizzia, Francesca Casellia, Daniele Gianninib, Valeria Camilettia, Barbara Filenia, Andrea Giacomettia, Luigi Falconi Di Francescoa and Giorgio Scalisea

a Istituto di Malattie Infettive e Medicina Pubblica, Centro di Gestione Presidenza Medicina e Chirurgia, b Università degli Studi di Ancona, Ancona, Italy

The new antifungal derivative posaconazole was tested against three clinical isolates of Cryptococcus neoformans var. neoformans using a broth microdilution procedure performed according to the guidelines established by the NCCLS. Posaconazole MICs were 0.125, 0.25 and 1.0 mg/L for isolates 491, 2337 and 486, respectively. To investigate the in vivo activity of this new compound, we established an experimental model of systemic cryptococcosis in CD1 mice by iv injection of cells of each strain of C. neoformans. Low (3 mg/kg/day) and high (10 mg/kg/day) doses of posaconazole were compared with amphotericin B given at 0.3 mg/kg/day for 10 consecutive days. Survival studies showed that all treatment regimens were effective in prolonging the survival of mice infected with C. neoformans 486 (P < 0.001). Only posaconazole at 10 mg/kg and amphotericin B were effective in prolonging the survival in mice infected with C. neoformans 2337 (P from <0.01 to <0.001), while neither agent was effective in mice infected with C. neoformans 491. Tissue burden experiments performed 24 h after the end of therapy revealed that posaconazole at 10 mg/kg was effective at reducing the fungal burden in both lung and brain tissues of all three strains of C. neoformans. In particular, for C. neoformans 491 and 2337 posaconazole was superior to amphotericin B at reducing the fungal burden in the brain (P < 0.05). The efficacy of posaconazole was also confirmed by determining the capsular antigen serum levels of treated mice versus untreated mice. Our study underlines the excellent activity of posaconazole against this pathogenic yeast.

* Correspondence address. Istituto di Malattie Infettive e Medicina Pubblica, Università degli Studi di Ancona, Azienda Ospedaliera Umberto I°, Via Conca –Torrette, 60020, Ancona, Italy. Tel: +39-71-5963467; Fax: +39-71-5963468; E-mail: cmalinf{at}popcsi.unian.it


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J Antimicrob ChemotherHome page
A.-J. Carrillo-Munoz, G. Quindos, M. Ruesga, R. Alonso, O. del Valle, J. M. Hernandez-Molina, P. McNicholas, D. Loebenberg, and P. Santos
Antifungal activity of posaconazole compared with fluconazole and amphotericin B against yeasts from oropharyngeal candidiasis and other infections
J. Antimicrob. Chemother., March 1, 2005; 55(3): 317 - 319.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
J. K. Imai, G. Singh, K. V. Clemons, and D. A. Stevens
Efficacy of Posaconazole in a Murine Model of Central Nervous System Aspergillosis
Antimicrob. Agents Chemother., October 1, 2004; 48(10): 4063 - 4066.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
P. Krieter, B. Flannery, T. Musick, M. Gohdes, M. Martinho, and R. Courtney
Disposition of Posaconazole following Single-Dose Oral Administration in Healthy Subjects
Antimicrob. Agents Chemother., September 1, 2004; 48(9): 3543 - 3551.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
R. Courtney, E. Radwanski, J. Lim, and M. Laughlin
Pharmacokinetics of Posaconazole Coadministered with Antacid in Fasting or Nonfasting Healthy Men
Antimicrob. Agents Chemother., March 1, 2004; 48(3): 804 - 808.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
A. Ghosal, N. Hapangama, Y. Yuan, J. Achanfuo-Yeboah, R. Iannucci, S. Chowdhury, K. Alton, J. E. Patrick, and S. Zbaida
IDENTIFICATION OF HUMAN UDP-GLUCURONOSYLTRANSFERASE ENZYME(S) RESPONSIBLE FOR THE GLUCURONIDATION OF POSACONAZOLE (NOXAFIL)
Drug Metab. Dispos., February 1, 2004; 32(2): 267 - 271.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
R. Courtney, S. Pai, M. Laughlin, J. Lim, and V. Batra
Pharmacokinetics, Safety, and Tolerability of Oral Posaconazole Administered in Single and Multiple Doses in Healthy Adults
Antimicrob. Agents Chemother., September 1, 2003; 47(9): 2788 - 2795.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.